{
    "guideline_identifier": "PIIS0923753421048274.txt",
    "cancer_focus": {
        "primary_cancer": "Urothelial Carcinoma (Bladder Cancer)",
        "related_syndrome_or_condition": "Upper Tract Urothelial Carcinoma (UTUC); Variant Histologies (squamous, adenocarcinoma, nested, micropapillary, plasmacytoid, sarcomatoid, small cell neuroendocrine)"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Non-Muscle Invasive (NMIBC) (Ta/T1/Tis)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "clinical_context": "Solitary Ta LG tumor ≤3 cm, no CIS",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Immediate intravesical chemotherapy post-TURBT + surveillance",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Non-Muscle Invasive (NMIBC) (Ta/T1/Tis)",
            "risk_group": "Intermediate risk",
            "treatment_plans": [
                {
                    "clinical_context": "Tumors not fitting low/high criteria",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Intravesical chemotherapy (max 1 year) or 1-year BCG (induction + maintenance)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Non-Muscle Invasive (NMIBC) (Ta/T1/Tis)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "T1 HG, CIS, multiple/large/recurrent tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "1–3 years BCG maintenance or radical cystectomy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Non-Muscle Invasive (NMIBC) (Ta/T1/Tis)",
            "risk_group": "Very High risk",
            "treatment_plans": [
                {
                    "clinical_context": "T1 HG + CIS, prostatic urethra involvement, variant histology",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Radical cystectomy (preferred) or BCG + 3-year maintenance",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Non-Muscle Invasive (NMIBC) (Ta/T1/Tis)",
            "risk_group": "BCG-Unresponsive",
            "treatment_plans": [
                {
                    "clinical_context": "BCG failure",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Radical cystectomy",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III B"
                },
                {
                    "clinical_context": "BCG failure alternatives",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab/nadofaragene firadenovec",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III C"
                },
                {
                    "clinical_context": "BCG failure alternatives",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Thermo-chemotherapy",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II B"
                }
            ]
        },
        {
            "staging_criteria": "Muscle-Invasive (MIBC) (cT2–T4a)",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Localized MIBC",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Radical cystectomy (RC) + pelvic lymph node dissection (PLND)",
                    "treatment_line": "Curative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Organ preservation candidates",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Trimodal therapy (TURBT + chemoradiation)",
                    "treatment_line": "Curative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II B"
                },
                {
                    "clinical_context": "Preoperative management",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Neoadjuvant cisplatin-based chemotherapy (3–4 cycles)",
                    "treatment_line": "Neoadjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Chemo-naïve post-surgery",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Adjuvant cisplatin-based chemotherapy",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II B"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic (M1)",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Cisplatin-eligible first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Gemcitabine/cisplatin → maintenance avelumab if no progression",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Cisplatin-ineligible first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Gemcitabine/carboplatin → maintenance avelumab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Cisplatin-ineligible PD-L1+ first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Atezolizumab or pembrolizumab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "Positive",
                            "testing_guidance": "SP142 assay for atezolizumab; 22C3 assay for pembrolizumab (per EMA guidelines)"
                        }
                    ],
                    "esmo_evidence_level": "III B"
                },
                {
                    "clinical_context": "Post-platinum second-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Post-platinum second-line alternative",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Atezolizumab",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II B"
                },
                {
                    "clinical_context": "FGFR-altered tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Erdafitinib",
                    "treatment_line": "Targeted therapy",
                    "biomarker_requirements": [
                        {
                            "name": "FGFR2/3",
                            "status": "Mutations/Fusions",
                            "testing_guidance": "NGS or PCR testing required"
                        }
                    ],
                    "esmo_evidence_level": "III B"
                },
                {
                    "clinical_context": "Post-immunotherapy/refractory",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Enfortumab vedotin",
                    "treatment_line": "Later-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Platinum-sensitive recurrence (>12-month interval)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum rechallenge",
                    "treatment_line": "Later-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV B"
                }
            ]
        },
        {
            "staging_criteria": "Upper Tract Urothelial Carcinoma (UTUC)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "clinical_context": "Localized UTUC",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Kidney-sparing surgery",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II B"
                }
            ]
        },
        {
            "staging_criteria": "Upper Tract Urothelial Carcinoma (UTUC)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Localized UTUC",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Radical nephroureterectomy + bladder cuff excision",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II B"
                },
                {
                    "clinical_context": "Post-surgery adjuvant",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Cisplatin-based chemotherapy",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II C"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "PD-L1 positivity predicts immunotherapy response in cisplatin-ineligible first-line metastatic UC; FGFR2/3 alterations predict erdafitinib efficacy in metastatic UC"
    }
}